You are here:

infliximab (Remicade)


Following a full submission

infliximab (Remicade) is not recommended for use within NHS Scotland for the treatment of moderately to severely active ulcerative colitis in patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine or azathioprine, or who are intolerant to or have medical contra-indications for such therapies.

As rescue therapy, infliximab has been shown to reduce the rate of colectomy compared with placebo in two small studies. However its relative efficacy and long-term benefits compared to existing management options remain unclear.

The manufacturer did not present a sufficiently robust economic case to gain acceptance by SMC.

Drug Details

Drug Name: infliximab (Remicade)
SMC Drug ID: 374/07
Manufacturer: Schering-Plough Ltd
Indication: Ulcerative colitis
BNF Category:
Sub Category: 1.5 Chronic bowel disorders
Submission Type: Full submission
Status: Not Recommended
Date Advice Published: 13 July 2009